FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300778269> ?p ?o ?g. }

• W4300778269 endingPage "1906" @default.
• W4300778269 startingPage "1903" @default.
• W4300778269 abstract "No AccessJournal of UrologyClinical Urology: Original Article1 Jun 1996Five-year Followup of a Prospective Trial of Radical Cystectomy and Neoadjuvant Chemotherapy: Nordic Cystectomy Trial 1 Per-Uno Malmstrom, Erkki Rintala, Rolf Wahlqvist, Pekka Hellstrom, Sverker Hellsten, and Einar Hannisdal Per-Uno MalmstromPer-Uno Malmstrom More articles by this author , Erkki RintalaErkki Rintala More articles by this author , Rolf WahlqvistRolf Wahlqvist More articles by this author , Pekka HellstromPekka Hellstrom More articles by this author , Sverker HellstenSverker Hellsten More articles by this author , and Einar HannisdalEinar Hannisdal More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)66042-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Chemotherapy is widely used in patients with locally advanced bladder cancer but until now there has been no conclusive evidence that this therapy improves survival. The Nordic Cooperative Bladder Cancer Study Group conducted a randomized phase III study to assess the possible benefit of neoadjuvant chemotherapy in patients with bladder cancer undergoing radical cystectomy after short-term radiotherapy. Materials and Methods: Our trial included 325 patients with locally advanced stage T1 grade 3 or stages T2 to T4aNXMO bladder cancer allocated randomly into a chemotherapy or no chemotherapy group (control). The chemotherapy schedule consisted of 2 cycles of 70 mg./m.2 cisplatin and 30 mg./m.2 doxorubicin with a 3-week interval between the cycles. Results: After 5 years the overall survival rate was 59 percent in the chemotherapy group and 51 percent in the control group (p = 0.1). The corresponding cancer specific survival rate was 64 and 54 percent, respectively. In regard to treatment, no difference was observed for stages T1 and T2 disease, while there was a 15 percent difference in overall survival for patients with stages T3 to T4a disease (p = 0.03). In a multivariate analysis only chemotherapy and T category emerged as independent prognostic factors. The relative death risk for patients who received chemotherapy was 0.69 (95 percent confidence interval 0.49 to 0.98) compared to the control group after adjustment for the other tested factors. Conclusions: Neoadjuvant chemotherapy seems to improve long-term survival after cystectomy in patients with stages T3 to T4a bladder carcinoma, while no survival benefit was found for stages T1 to T2 disease. References 1 : Current management of invasive and metastatic transitional cell carcinoma of the bladder. J. Urol.1993; 149: 957. Link, Google Scholar 2 : Radical cystectomy and adjuvant chemotherapy. Urology1985; 25: 151. Google Scholar 3 : Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand. J. Urol. Nephrol.1993; 27: 355. Google Scholar 4 : Bladder carcinoma as a systemic disease. Cancer1979; 43: 2532. Google Scholar 5 : Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. Brit. J. Urol.1988; 62: 558. Google Scholar 6 : Neo-adjuvant (preemptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Brit. J. Urol.1991; 67: 608. Google Scholar 7 : Neoadjuvant and classic adjuvant chemotherapy for bladder cancer. Curr. Opin. Urol.1991; 1: 53. Google Scholar 8 : Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J. Urol.1995; 153: 964. Google Scholar 9 : Local recurrence after cystectomy alone for bladder carcinoma. Cancer1992; 69: 2767. Crossref, Medline, Google Scholar 10 : The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer1993; 71: 3993. Crossref, Medline, Google Scholar 11 : Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Brit. J. Urol.1995; 75: 206. Google Scholar 12 : A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer1993; 72: 3044. Google Scholar From the Departments of Urology, University Hospital Uppsala, Uppsala, and University Hospital, Malmo, Sweden, Helsinki University Central Hospital, Helsinki and Oulu University Hospital, Oulu, Finland, and Ulleval sykehus, Oslo, and Clinical Research Office, Norwegian Radium Hospital, Oslo, Norway.© 1996 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byFischer-Valuck B, Rao Y, Rudra S, Przybysz D, Germino E, Samson P, Baumann B, Gay H and Michalski J (2017) Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer DatabaseJournal of Urology, VOL. 199, NO. 2, (416-423), Online publication date: 1-Feb-2018.Traboulsi S and Kassouf W (2015) A Review of Neoadjuvant and Adjuvant Chemotherapy for Nonmetastatic Muscle Invasive Bladder CancerUrology Practice, VOL. 3, NO. 1, (41-49), Online publication date: 1-Jan-2016.North S, El-Gehani F, Santos C, Ghosh S, Lai R, Cass C and Mackey J (2013) Expression of Nucleoside Transporters and Deoxycytidine Kinase Proteins in Muscle Invasive Urothelial Carcinoma of the Bladder: Correlation with Pathological Response to Neoadjuvant Platinum/Gemcitabine Combination ChemotherapyJournal of Urology, VOL. 191, NO. 1, (35-39), Online publication date: 1-Jan-2014.Mertens L, Fioole-Bruining A, van Rhijn B, Kerst J, Bergman A, Vogel W, Vegt E and Horenblas S (2012) FDG-Positron Emission Tomography/Computerized Tomography for Monitoring the Response of Pelvic Lymph Node Metastasis to Neoadjuvant Chemotherapy for Bladder CancerJournal of Urology, VOL. 189, NO. 5, (1687-1691), Online publication date: 1-May-2013.Mertens L, Meijer R, Kerst J, Bergman A, van Tinteren H, van Rhijn B and Horenblas S (2012) Carboplatin Based Induction Chemotherapy for Nonorgan Confined Bladder Cancer—A Reasonable Alternative for Cisplatin Unfit Patients?Journal of Urology, VOL. 188, NO. 4, (1108-1114), Online publication date: 1-Oct-2012.Eswara J, Efstathiou J, Heney N, Paly J, Kaufman D, McDougal W, McGovern F and Shipley W (2011) Complications and Long-Term Results of Salvage Cystectomy After Failed Bladder Sparing Therapy for Muscle Invasive Bladder CancerJournal of Urology, VOL. 187, NO. 2, (463-468), Online publication date: 1-Feb-2012.David K, Milowsky M, Ritchey J, Carroll P and Nanus D (2007) Low Incidence of Perioperative Chemotherapy for Stage III Bladder Cancer 1998 to 2003: A Report From the National Cancer Data BaseJournal of Urology, VOL. 178, NO. 2, (451-454), Online publication date: 1-Aug-2007.ROSENBERG J, CARROLL P and SMALL E (2018) UPDATE ON CHEMOTHERAPY FOR ADVANCED BLADDER CANCERJournal of Urology, VOL. 174, NO. 1, (14-20), Online publication date: 1-Jul-2005.WINQUIST E, KIRCHNER T, SEGAL R, CHIN J and LUKKA H (2018) Neoadjuvant Chemotherapy for Transitional Cell Carcinoma of the Bladder: A Systematic Review and Meta-AnalysisJournal of Urology, VOL. 171, NO. 2, (561-569), Online publication date: 1-Feb-2004.KIM H and STEINBERG G (2018) THE CURRENT STATUS OF BLADDER PRESERVATION IN THE TREATMENT OF MUSCLE INVASIVE BLADDER CANCERJournal of Urology, VOL. 164, NO. 3 Part 1, (627-632), Online publication date: 1-Sep-2000.ENNIS R, PETRYLAK D, SINGH P, BAGIELLA E, O’TOOLE K, BENSON M and OLSSON C (2018) THE EFFECT OF CYSTECTOMY, AND PERIOPERATIVE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN CHEMOTHERAPY ON THE RISK AND PATTERN OF RELAPSE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCERJournal of Urology, VOL. 163, NO. 5, (1413-1418), Online publication date: 1-May-2000.Raghavan D (2018) EDITORIAL: BLADDER PRESERVATION IN PATIENTS WITH BLADDER CANCER-QUALITY VERSUS QUANTITY OF LIFE?Journal of Urology, VOL. 160, NO. 5, (1678-1679), Online publication date: 1-Nov-1998.SERRETTA V, LO GRECO G, PAVONE C and PAVONE-MACALUSO M (2018) THE FATE OF PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER TREATED CONSERVATIVELY WITH NEOADJUVANT CHEMOTHERAPY, EXTENSIVE TRANSURETHRAL RESECTION AND RADIOTHERAPY: 10-YEAR EXPERIENCEJournal of Urology, VOL. 159, NO. 4, (1187-1191), Online publication date: 1-Apr-1998.Ghoneim M, El-Mekresh M, El-Baz M, El-Attar I and Ashamallah A (2018) Radical Cystectomy for Carcinoma of the Bladder: Critical Evaluation of the Results in 1,026 CasesJournal of Urology, VOL. 158, NO. 2, (393-399), Online publication date: 1-Aug-1997.Holmang S, Hedelin H, Anderstrom C and Johansson S (2018) Long-Term Followup of all Patients with Muscle Invasive (Stages T2, T3 and T4) Bladder Carcinoma in a Geographical RegionJournal of Urology, VOL. 158, NO. 2, (389-392), Online publication date: 1-Aug-1997. Volume 155Issue 6June 1996Page: 1903-1906 Advertisement Copyright & Permissions© 1996 by American Urological Association, Inc.Metrics Author Information Per-Uno Malmstrom More articles by this author Erkki Rintala More articles by this author Rolf Wahlqvist More articles by this author Pekka Hellstrom More articles by this author Sverker Hellsten More articles by this author Einar Hannisdal More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4300778269 created "2022-10-04" @default.
• W4300778269 creator A5005539558 @default.
• W4300778269 creator A5011785241 @default.
• W4300778269 creator A5012505594 @default.
• W4300778269 creator A5039402380 @default.
• W4300778269 creator A5049779157 @default.
• W4300778269 creator A5086024786 @default.
• W4300778269 date "1996-06-01" @default.
• W4300778269 modified "2023-10-16" @default.
• W4300778269 title "Five-year Followup of a Prospective Trial of Radical Cystectomy and Neoadjuvant Chemotherapy: Nordic Cystectomy Trial 1" @default.
• W4300778269 cites W117818932 @default.
• W4300778269 cites W1973794035 @default.
• W4300778269 cites W2011729580 @default.
• W4300778269 cites W2022837219 @default.
• W4300778269 cites W2027258990 @default.
• W4300778269 cites W2033680871 @default.
• W4300778269 cites W2039727890 @default.
• W4300778269 cites W2045447142 @default.
• W4300778269 cites W2047013318 @default.
• W4300778269 cites W2061282788 @default.
• W4300778269 cites W2765715014 @default.
• W4300778269 cites W4245152549 @default.
• W4300778269 doi "https://doi.org/10.1016/s0022-5347(01)66042-7" @default.
• W4300778269 hasPublicationYear "1996" @default.
• W4300778269 type Work @default.
• W4300778269 citedByCount "175" @default.
• W4300778269 countsByYear W43007782692012 @default.
• W4300778269 countsByYear W43007782692013 @default.
• W4300778269 countsByYear W43007782692014 @default.
• W4300778269 countsByYear W43007782692015 @default.
• W4300778269 countsByYear W43007782692016 @default.
• W4300778269 countsByYear W43007782692018 @default.
• W4300778269 countsByYear W43007782692019 @default.
• W4300778269 countsByYear W43007782692020 @default.
• W4300778269 countsByYear W43007782692021 @default.
• W4300778269 countsByYear W43007782692022 @default.
• W4300778269 countsByYear W43007782692023 @default.
• W4300778269 crossrefType "journal-article" @default.
• W4300778269 hasAuthorship W4300778269A5005539558 @default.
• W4300778269 hasAuthorship W4300778269A5011785241 @default.
• W4300778269 hasAuthorship W4300778269A5012505594 @default.
• W4300778269 hasAuthorship W4300778269A5039402380 @default.
• W4300778269 hasAuthorship W4300778269A5049779157 @default.
• W4300778269 hasAuthorship W4300778269A5086024786 @default.
• W4300778269 hasConcept C121608353 @default.
• W4300778269 hasConcept C126322002 @default.
• W4300778269 hasConcept C126894567 @default.
• W4300778269 hasConcept C141071460 @default.
• W4300778269 hasConcept C143998085 @default.
• W4300778269 hasConcept C2775910329 @default.
• W4300778269 hasConcept C2776694085 @default.
• W4300778269 hasConcept C2778292576 @default.
• W4300778269 hasConcept C2780352672 @default.
• W4300778269 hasConcept C530470458 @default.
• W4300778269 hasConcept C61434518 @default.
• W4300778269 hasConcept C71924100 @default.
• W4300778269 hasConceptScore W4300778269C121608353 @default.
• W4300778269 hasConceptScore W4300778269C126322002 @default.
• W4300778269 hasConceptScore W4300778269C126894567 @default.
• W4300778269 hasConceptScore W4300778269C141071460 @default.
• W4300778269 hasConceptScore W4300778269C143998085 @default.
• W4300778269 hasConceptScore W4300778269C2775910329 @default.
• W4300778269 hasConceptScore W4300778269C2776694085 @default.
• W4300778269 hasConceptScore W4300778269C2778292576 @default.
• W4300778269 hasConceptScore W4300778269C2780352672 @default.
• W4300778269 hasConceptScore W4300778269C530470458 @default.
• W4300778269 hasConceptScore W4300778269C61434518 @default.
• W4300778269 hasConceptScore W4300778269C71924100 @default.
• W4300778269 hasIssue "6" @default.
• W4300778269 hasLocation W43007782691 @default.
• W4300778269 hasOpenAccess W4300778269 @default.
• W4300778269 hasPrimaryLocation W43007782691 @default.
• W4300778269 hasRelatedWork W1987461627 @default.
• W4300778269 hasRelatedWork W2105895425 @default.
• W4300778269 hasRelatedWork W2367105124 @default.
• W4300778269 hasRelatedWork W2535237470 @default.
• W4300778269 hasRelatedWork W2603025253 @default.
• W4300778269 hasRelatedWork W2980761415 @default.
• W4300778269 hasRelatedWork W3092055942 @default.
• W4300778269 hasRelatedWork W3202848091 @default.
• W4300778269 hasRelatedWork W4229366546 @default.
• W4300778269 hasRelatedWork W4315628570 @default.
• W4300778269 hasVolume "155" @default.
• W4300778269 isParatext "false" @default.
• W4300778269 isRetracted "false" @default.
• W4300778269 workType "article" @default.